Literature DB >> 18948313

Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies.

Willem de Ronde1.   

Abstract

Topically applied testosterone gels are a widely used mode of testosterone replacement therapy. A concern associated with the use of testosterone gel is unintentional transfer to children or women by skin contact with the application site. We present a case of female hyperandrogenism most likely caused by transfer of testosterone gel used by her partner. Additionally, we searched the computerized database PUBMED and the FDA medical reviews for case reports and clinical trials concerning transfer risk. Several case reports and the results of clinical trials indicate that transfer of testosterone from gel-treated males to women and children is possible and clinically relevant. Thus, the potential of testosterone transfer in gel users should be recognized as a possible side effect of this form of testosterone replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18948313     DOI: 10.1093/humrep/den372

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  16 in total

1.  Pharmacokinetics of modified slow-release oral testosterone over 9 days in normal men with experimental hypogonadism.

Authors:  Ada Lee; Katya Rubinow; Richard V Clark; Ralph B Caricofe; Mark A Bush; Hui Zhi; Mara Y Roth; Stephanie T Page; William J Bremner; John K Amory
Journal:  J Androl       Date:  2011-08-25

2.  Pharmacokinetics of 2 novel formulations of modified-release oral testosterone alone and with finasteride in normal men with experimental hypogonadism.

Authors:  Christin N Snyder; Richard V Clark; Ralph B Caricofe; Mark A Bush; Mara Y Roth; Stephanie T Page; William J Bremner; John K Amory
Journal:  J Androl       Date:  2010-04-08

3.  Oral testosterone with and without concomitant inhibition of 5α-reductase by dutasteride in hypogonadal men for 28 days.

Authors:  John K Amory; Mark A Bush; Hui Zhi; Ralph B Caricofe; Alvin M Matsumoto; Ronald S Swerdloff; Christina Wang; Richard V Clark
Journal:  J Urol       Date:  2010-12-18       Impact factor: 7.450

4.  Prenatal virilization associated with paternal testosterone gel therapy.

Authors:  Anisha Patel; Scott A Rivkees
Journal:  Int J Pediatr Endocrinol       Date:  2010-10-07

5.  Patient satisfaction with testosterone replacement therapies: the reasons behind the choices.

Authors:  Jason R Kovac; Saneal Rajanahally; Ryan P Smith; Robert M Coward; Dolores J Lamb; Larry I Lipshultz
Journal:  J Sex Med       Date:  2013-11-06       Impact factor: 3.802

6.  Induction of androgen formation in the male by a TAT-VDAC1 fusion peptide blocking 14-3-3ɛ protein adaptor and mitochondrial VDAC1 interactions.

Authors:  Yasaman Aghazadeh; Daniel B Martinez-Arguelles; Jinjiang Fan; Martine Culty; Vassilios Papadopoulos
Journal:  Mol Ther       Date:  2014-06-20       Impact factor: 11.454

Review 7.  The practical management of testosterone deficiency in men.

Authors:  Antonio Aversa; Abraham Morgentaler
Journal:  Nat Rev Urol       Date:  2015-10-13       Impact factor: 14.432

8.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

Review 9.  Safety and efficacy of testosterone gel in the treatment of male hypogonadism.

Authors:  Kishore M Lakshman; Shehzad Basaria
Journal:  Clin Interv Aging       Date:  2009-11-18       Impact factor: 4.458

10.  Impact of early postnatal androgen exposure on voice development.

Authors:  Leila Grisa; Maria L Leonel; Maria I R Gonçalves; Francisco Pletsch; Elis R Sade; Gislaine Custódio; Ivete P S Zagonel; Carlos A Longui; Bonald C Figueiredo
Journal:  PLoS One       Date:  2012-12-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.